Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: A Children's Oncology Group study

Cancer

Volumn 104, Issue 4, 2005, Pages 841-847

  Marina, Neyssa ^a   Chang, Kay W ^a   Malogolowkin, Marcio ^b   London, Wendy B ^c   Frazier, A Lindsay ^d   Womer, Richard B ^e   Rescorla, Frederick ^f   Billmire, Deborah F ^f   Davis, Mary M ^f   Perlman, Elizabeth J ^g   Giller, Roger ^h   Lauer, Stephen J ⁱ   Olson, Thomas A ⁱ  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Children's Oncology Group ^*  (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f INDIANA UNIVERSITY   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h CHILDREN S HOSPITAL   (United States)

ⁱ Children's Healthcare of Atlanta at Egleston ^*  (United States)

Author keywords

Bleomycin; Etoposide; High dose cisplatin; Pediatric germ cell tumors

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ARTICLE; AUDIOLOGY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HEARING LOSS; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; INFANT; MALE; METASTASIS; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTOPENIA;

ADOLESCENT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; ETOPOSIDE; FEMALE; HEARING DISORDERS; HUMANS; INFANT; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PILOT PROJECTS; RADIATION-PROTECTIVE AGENTS;

EID: 23444455599     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21218     Document Type: Article

References (41)

1. Mulligan RM. Pathogenesis of teratoid tumors of the ovary and testis. Pathol Annu. 1975;10:271-298.
2. Billmire D, Grosfeld J. Teratomas in childhood: analysis of 142 cases. J Pediatr Surg. 1986;21:548-55.
3. Chretien P, Milam J, Foote F. Embryonal adenocarcinomas (a type of malignant teratoma) of the sacrococcygeal region. Clinical and pathologic aspects of 21 cases. Cancer. 1970;26:522-535.
4. Kurman R, Norris H. Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer. 1976; 38:2404-2419.
5. Einhorn LH, Donohue J. Cis-diaminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87:293-298.
6. Peckham MJ, Horwich A, Blackmore C, Hendry WF. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Cancer Treat Rep. 1985;69: 483-488.
7. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9:1163-1172.
8. Loehrer PJ Sr., Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470-476.
9. Einhorn LH. Testicular cancer: an oncological success story. Clin Cancer Res. 1997;12:2630-2632.
10. Pinkerton C, Pritchard J, Spitz L. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy. J Clin Oncol. 1986;4:194-199.
11. Exelby PR. Testicular cancer in children. Cancer. 1980; 45(7 Suppl):1803-1809.
12. Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12:313-317.
13. Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol. 1992;19(2 Suppl 5):64-70.
14. Mann JR, Pearson D, Barrett A, Raafat F, Barnes JM, Wallendszus KR. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer. 1989;63:1657-1667.
15. Chiuten D, Vogl S, Kaplan B, Camacho F. Is there cumulative or delayed toxicity from cis-platinum? Cancer. 1983;52:211-214.
16. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000;18:3809-3818.
17. Baranzelli MC, Kramar A, Bouffet E, et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol. 1999;17:1212-1218.
18. Gobel U, Bamberg M, Engert J, et al. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study]. Klin Padiatr. 1991;203:236-245.
19. Gobel U, Calaminus G, Schneider DT, Schmidt P, Haas RJ. Management of germ cell tumors in children: approaches to cure. Onkologie. 2002;25:14-22.
20. Gobel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol. 2001;19: 1943-1950.
21. Ghosn M, Droz JP, Theodore C, et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhF regimen. Cancer. 1988;62:24-27.
22. Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Messerschmidt GL, Young RC. Treatment of poor prognosis non-seminomatous testicular cancer with a "high-dose" of platinum combination chemotherapy regimen. Cancer. 1983;51: 1803-1807.
23. Hartmann O, Pinkerton CR, Philip T, Zucker JM, Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6: 44-50.
24. Perin G, Dallorso S, Stura M, et al. High-dose cisplatin and etoposide in advanced malignancies of childhood. Pediatr Hematol Oncol. 1987;4:329-336.
25. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a Pediatric Intergroup Study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004;22:2691-2700.
26. Fulda S, Oster W, Berthold F. Effects of wr-2721 (amifostine) and its metabolite wr-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anticancer Drugs. 1997;8:34-41.
27. Borsi JD, Csaki C, Ferencz T, Oster W. Administration of ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anticancer Drugs. 1996;7:121-126.
28. Adamson PC, Balls FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995;55:4069-4072.
29. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 1997;80:1134-1140.
30. Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574-578.
31. Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol. 1986; 4:584-588.
32. Wadler S, Beider JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and wr2721 in carcinoma of the uterine cervix: a New York gynecologic oncology group study. J Clin Oncol. 1993;11:1511-1516.
33. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
34. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295-300.
35. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445-2451.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
37. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A. 1972;135:185-198.
38. Einhorn LH. Combination chemotherapy with cis- dichlorodiammineplatinum(II) in disseminated testicular cancer. Cancer Treat Rep. 1979;63:1659-1662.
39. Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer. West J Med. 1979;131:1-3.
40. Katzenstein HM, Chang K, Krailo M, et al. A randomized study of platinum based chemotherapy with or without amifostine for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645 [abstract]. Am Soc Clin Oncol. 2004;22:8518.
41. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784.